Depok, June 19, 2026 – Another remarkable achievement has been made by a faculty member of the Faculty of Mathematics and Natural Sciences, Universitas Indonesia (FMIPA UI). A radiopharmaceutical dosimetry method developed by Dr. sc. hum. Deni Hardiansyah, S.Pd., M.Si., a lecturer at the Department of Physics, FMIPA UI, is now being utilized and incorporated into technology development at ITM Isotope Technologies Munich SE (ITM), one of Europe’s leading radiopharmaceutical companies headquartered in Garching, Munich, Germany.
Dr. Deni’s contribution was highlighted during the presentation of research findings at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2026, held in Los Angeles, United States. The study utilized the method developed by Dr. Deni and his team to support more accurate, efficient, and personalized radiopharmaceutical-based cancer therapy.
The method developed by Dr. Deni consists of two main approaches: Population-Based Modeling and Simulation Nonlinear Mixed Effects Modeling (PBMS NLME) and Single-Timepoint (STP) Dosimetry. PBMS NLME is a statistical approach designed to identify the most appropriate mathematical model for calculating individualized radiation absorbed doses. This method has been shown to provide more accurate dose estimates than the dosimetry approaches that have been widely used in the scientific literature.
Meanwhile, Single-Timepoint (STP) Dosimetry enables the measurement of radiation absorbed doses using only a single scan. This approach represents a significant breakthrough, as conventional methods generally require three to five separate measurements to obtain sufficiently reliable results. In addition to reducing the burden on patients and lowering hospital resource requirements, the method has also demonstrated higher accuracy than various single-timepoint dosimetry approaches previously reported in the literature.
In the study presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2026, the PBMS NLME method was applied to dosimetry data from the Phase III COMPETE Trial clinical trial involving patients with Gastroenteropancreatic Neuroendocrine Tumors. Analysis of hundreds of kidney and tumor datasets demonstrated that the PBMS NLME approach was capable of providing accurate estimates of radiation absorbed doses using only a single imaging session. These findings open new opportunities for the broader implementation of personalized dosimetry across healthcare facilities, including treatment centers with limited imaging capacity.
The findings have also received official recognition from ITM Isotope Technologies Munich SE. In a company press release entitled “ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026”, ITM stated that PBMS NLMEM-based analysis of data from the Phase III COMPETE clinical trial demonstrated that accurate individualized dosimetry can be achieved with only a single imaging session. The release also cited Dr. Deni Hardiansyah as one of the authors and researchers involved in the development of the method.
The official ITM press release is available on the company’s website:
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for ITM-11 at SNMMI 2026
“Individualized dosimetry has long been recognized as having significant clinical value in radiopharmaceutical therapy. However, its implementation has remained limited due to the complexity of repeated imaging requirements. These findings demonstrate that a population modeling–based approach can provide accurate dose estimates with substantially fewer measurements, making it more feasible for routine clinical practice,” said Dr. Deni Hardiansyah, who is also a co-author of the publication.
The adoption of a method developed by an FMIPA UI faculty member by a world-class radiopharmaceutical company demonstrates that academic research from Indonesia is capable of making a tangible contribution to the advancement of global healthcare technology. The implementation of this method has the potential to accelerate the adoption of more effective, safer, and more affordable precision cancer therapies for patients around the world.
This achievement also serves as evidence of FMIPA UI’s growing presence and contribution on the global stage. Through international collaborations and research driven by societal needs, FMIPA UI continues to contribute to the development of innovations that provide tangible benefits for the advancement of science and healthcare technology. The adoption of the method developed by Dr. Deni Hardiansyah further demonstrates that innovations originating from Indonesia’s academic community are capable of making a meaningful impact on the development of global healthcare technologies.
